Claudin 18.2 Targeted Therapy Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Claudin 18.2 Targeted Therapy Market Report 2026

Name: Claudin 18.2 Targeted Therapy Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Therapy Type (Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types), By Indication (Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications), By Route Of Administration (Intravenous, Oral, Other Route Of Administrations), By End-User (Hospitals, Oncology Centers, Research Institutes, Other End-Users) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Claudin 18.2 Targeted Therapy Market Overview

• Claudin 18.2 Targeted Therapy market size has reached to $1.6 billion in 2025

• Expected to grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 23.5%

• Growth Driver: Rising Gastrointestinal Cancer Incidence Driving The Market Growth Due To Increasing Prevalence And Unhealthy Diets

• Market Trend: Prominent Companies Pioneering Targeted Oncology Solutions

• Asia-Pacific was the largest region in 2025.

What Is Covered Under Claudin 18.2 Targeted Therapy Market?

Claudin 18.2 targeted therapy is an advanced precision cancer treatment designed to specifically target the Claudin 18.2 protein, abnormally overexpressed on the surface of certain tumor cells. This therapy selectively attacks cancer cells, improving treatment efficacy and reducing damage to healthy tissues.

The main therapy types of claudin 18.2 targeted therapy are monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are lab-made molecules designed to attach to specific proteins on cancer cells, helping the immune system target and destroy them. These therapies are mainly indicated for gastric cancer, pancreatic cancer, esophageal cancer, and others, and are administered via intravenous, oral, and other routes. The therapies are primarily used by end-users, including hospitals, oncology centers, research institutes, and others.

Claudin 18.2 Targeted Therapy Market Global Report 2026 Market Report bar graph

What Is The Claudin 18.2 Targeted Therapy Market Size and Share 2026?

The claudin 18.2 targeted therapy market size has grown exponentially in recent years. It will grow from $1.6 billion in 2025 to $1.98 billion in 2026 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to increasing prevalence of gastric and gastrointestinal cancers, advancements in antibody engineering technologies, expansion of oncology-focused clinical trials, rising investments in targeted cancer therapies, improved understanding of claudin protein biology.

What Is The Claudin 18.2 Targeted Therapy Market Growth Forecast?

The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted oncology drugs, rising demand for personalized cancer treatment, expansion of combination therapy approaches, growing oncology pipeline investments, increasing adoption of precision diagnostics. Major trends in the forecast period include increasing focus on biomarker-driven oncology therapies, rising development of claudin 18.2 monoclonal antibodies, growing expansion of indication-specific targeted treatments, enhanced integration of companion diagnostics, increasing strategic collaborations in precision oncology.

Book your 30 minutes free consultation with our research experts

Global Claudin 18.2 Targeted Therapy Market Segmentation

1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types

2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications

3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies

3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates

4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

What Is The Driver Of The Claudin 18.2 Targeted Therapy Market?

The rising incidence of gastrointestinal cancers is expected to propel the growth of the claudin 18.2 targeted therapy market going forward. Gastrointestinal (GI) cancers refer to malignant tumors that develop in any part of the digestive tract, from the esophagus to the rectum. The rise in gastrointestinal cancers is largely due to unhealthy diets rich in processed foods and low in fiber, promoting gut inflammation and increasing cancer risk. Claudin 18.2 targeted therapy helps treat gastrointestinal cancers by selectively targeting the Claudin 18.2 protein, overexpressed on cancer cells, enabling drugs or antibodies to kill cancer cells while sparing healthy tissue and improving treatment effectiveness. For instance, in June 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 147,931 new colorectal cancer cases were reported in 2022, and 53,779 deaths from colorectal cancer were recorded in 2023. Therefore, the rising incidence of gastrointestinal cancers is driving the growth of the Claudin 18.2 targeted therapy industry.

Key Players In The Global Claudin 18.2 Targeted Therapy Market

Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

Global Claudin 18.2 Targeted Therapy Market Trends and Insights

Major companies operating in the claudin 18.2 targeted therapy market are focusing on developing innovative solutions, such as monoclonal antibodies, to specifically target claudin 18.2-expressing cancer cells and enhance treatment outcomes. A monoclonal antibody is a laboratory-engineered protein designed to bind precisely to a single target, such as a protein on the surface of cancer cells, aiding the immune system in recognizing and attacking these cells. For instance, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, obtained approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on tumor cells, activating the immune system to destroy cancer cells. Clinical trials showed it significantly improves progression-free and overall survival when combined with chemotherapy compared to chemotherapy alone. This innovative therapy provides a new, effective option for patients with HER2-negative, CLDN18.2-positive tumors, fulfilling an unmet need in aggressive gastric cancer.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Claudin 18.2 Targeted Therapy Market?

In February 2024, AstraZeneca plc, a UK-based pharmaceutical industry company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to accelerate its cell therapy strategy by expanding its pipeline with Gracell's innovative CAR-T therapies targeting blood cancers and autoimmune diseases, leveraging Gracell’s FasTCAR platform to improve treatment efficacy and manufacturing speed. Gracell Biotechnologies Inc. is a China-based clinical-stage biopharmaceutical company that offers claudin 18.2 targeted therapy.

Regional Insights

Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Claudin 18.2 Targeted Therapy Market?

The claudin 18.2 targeted therapy market consists of sales of zolbetuximab, CMG901, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Claudin 18.2 Targeted Therapy Market Report 2026?

The claudin 18.2 targeted therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the claudin 18.2 targeted therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Claudin 18.2 Targeted Therapy Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$1.98 billion
Revenue Forecast In 2035	$4.61 billion
Growth Rate	CAGR of 23.7% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Therapy Type, Indication, Route Of Administration, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co.
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Claudin 18.2 Targeted Therapy Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Claudin 18.2 Targeted Therapy Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Claudin 18.2 Targeted Therapy Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Claudin 18.2 Targeted Therapy Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics And Precision Medicine

4.1.2 Artificial Intelligence And Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data And Cybersecurity

4.1.4 Industry 4.0 And Intelligent Manufacturing

4.1.5 Fintech, Blockchain, Regtech And Digital Finance

4.2. Major Trends

4.2.1 Increasing Focus On Biomarker-Driven Oncology Therapies

4.2.2 Rising Development Of Claudin 18.2 Monoclonal Antibodies

4.2.3 Growing Expansion Of Indication-Specific Targeted Treatments

4.2.4 Enhanced Integration Of Companion Diagnostics

4.2.5 Increasing Strategic Collaborations In Precision Oncology

5. Claudin 18.2 Targeted Therapy Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Oncology Centers

5.3 Research Institutes

5.4 Specialty Cancer Clinics

5.5 Academic Medical Centers

6. Claudin 18.2 Targeted Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Claudin 18.2 Targeted Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Claudin 18.2 Targeted Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Claudin 18.2 Targeted Therapy Market Size, Comparisons And Growth Rate Analysis

7.3. Global Claudin 18.2 Targeted Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Claudin 18.2 Targeted Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Claudin 18.2 Targeted Therapy Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Claudin 18.2 Targeted Therapy Market Segmentation

9.1. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types

9.2. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications

9.3. Global Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Intravenous, Oral, Other Route Of Administrations

9.4. Global Claudin 18.2 Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Oncology Centers, Research Institutes, Other End-Users

9.5. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

9.6. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies

9.7. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Microtubule Inhibitor-Based Antibody-Drug Conjugates, DNA Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates

9.8. Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

10. Claudin 18.2 Targeted Therapy Market Regional And Country Analysis

10.1. Global Claudin 18.2 Targeted Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Claudin 18.2 Targeted Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Claudin 18.2 Targeted Therapy Market

11.1. Asia-Pacific Claudin 18.2 Targeted Therapy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Claudin 18.2 Targeted Therapy Market

12.1. China Claudin 18.2 Targeted Therapy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Claudin 18.2 Targeted Therapy Market

13.1. India Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Claudin 18.2 Targeted Therapy Market

14.1. Japan Claudin 18.2 Targeted Therapy Market Overview

14.2. Japan Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Claudin 18.2 Targeted Therapy Market

15.1. Australia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Claudin 18.2 Targeted Therapy Market

16.1. Indonesia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Claudin 18.2 Targeted Therapy Market

17.1. South Korea Claudin 18.2 Targeted Therapy Market Overview

17.2. South Korea Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Claudin 18.2 Targeted Therapy Market

18.1. Taiwan Claudin 18.2 Targeted Therapy Market Overview

18.2. Taiwan Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Claudin 18.2 Targeted Therapy Market

19.1. South East Asia Claudin 18.2 Targeted Therapy Market Overview

19.2. South East Asia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Claudin 18.2 Targeted Therapy Market

20.1. Western Europe Claudin 18.2 Targeted Therapy Market Overview

20.2. Western Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Claudin 18.2 Targeted Therapy Market

21.1. UK Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Claudin 18.2 Targeted Therapy Market

22.1. Germany Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Claudin 18.2 Targeted Therapy Market

23.1. France Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Claudin 18.2 Targeted Therapy Market

24.1. Italy Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Claudin 18.2 Targeted Therapy Market

25.1. Spain Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Claudin 18.2 Targeted Therapy Market

26.1. Eastern Europe Claudin 18.2 Targeted Therapy Market Overview

26.2. Eastern Europe Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Claudin 18.2 Targeted Therapy Market

27.1. Russia Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Claudin 18.2 Targeted Therapy Market

28.1. North America Claudin 18.2 Targeted Therapy Market Overview

28.2. North America Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Claudin 18.2 Targeted Therapy Market

29.1. USA Claudin 18.2 Targeted Therapy Market Overview

29.2. USA Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Claudin 18.2 Targeted Therapy Market

30.1. Canada Claudin 18.2 Targeted Therapy Market Overview

30.2. Canada Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Claudin 18.2 Targeted Therapy Market

31.1. South America Claudin 18.2 Targeted Therapy Market Overview

31.2. South America Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Claudin 18.2 Targeted Therapy Market

32.1. Brazil Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Claudin 18.2 Targeted Therapy Market

33.1. Middle East Claudin 18.2 Targeted Therapy Market Overview

33.2. Middle East Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Claudin 18.2 Targeted Therapy Market

34.1. Africa Claudin 18.2 Targeted Therapy Market Overview

34.2. Africa Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Claudin 18.2 Targeted Therapy Market Regulatory and Investment Landscape

36. Claudin 18.2 Targeted Therapy Market Competitive Landscape And Company Profiles

36.1. Claudin 18.2 Targeted Therapy Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Claudin 18.2 Targeted Therapy Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Claudin 18.2 Targeted Therapy Market Company Profiles

36.3.1. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Jiangsu Hengrui Medicine Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Shanghai Henlius Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Claudin 18.2 Targeted Therapy Market Other Major And Innovative Companies

Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

38. Global Claudin 18.2 Targeted Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Claudin 18.2 Targeted Therapy Market

40. Claudin 18.2 Targeted Therapy Market High Potential Countries, Segments and Strategies

40.1 Claudin 18.2 Targeted Therapy Market In 2030 - Countries Offering Most New Opportunities

40.2 Claudin 18.2 Targeted Therapy Market In 2030 - Segments Offering Most New Opportunities

40.3 Claudin 18.2 Targeted Therapy Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Claudin 18.2 Targeted Therapy Market, Overview Of Key Products - Product Examples

Table 2: Global Claudin 18.2 Targeted Therapy Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Claudin 18.2 Targeted Therapy Market, Supply Chain Analysis

Table 4: Global Claudin 18.2 Targeted Therapy Market, Major Raw Material Providers

Table 5: Global Claudin 18.2 Targeted Therapy Market, Major Resource Providers

Table 6: Global Claudin 18.2 Targeted Therapy Market, Major Manufacturers (Suppliers)

Table 7: Global Claudin 18.2 Targeted Therapy Market, Major Distributors And Channel Partners

Table 8: Global Claudin 18.2 Targeted Therapy Market, Key Technologies & Future Trends

Table 9: Global Claudin 18.2 Targeted Therapy Market, Major Trends

Table 10: Global Claudin 18.2 Targeted Therapy Market, Major End Users

Table 11: Global Claudin 18.2 Targeted Therapy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Claudin 18.2 Targeted Therapy Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Claudin 18.2 Targeted Therapy Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Claudin 18.2 Targeted Therapy Market - TAM, US$ Billion, 2025

Table 15: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Claudin 18.2 Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Claudin 18.2 Targeted Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Claudin 18.2 Targeted Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Global Claudin 18.2 Targeted Therapy Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 98: Global Claudin 18.2 Targeted Therapy Market - Company Scoring Matrix

Table 99: Bristol Myers Squibb Company Financial Performance

Table 100: Amgen Inc. Financial Performance

Table 101: Astellas Pharma Inc. Financial Performance

Table 102: Jiangsu Hengrui Medicine Co. Ltd. Financial Performance

Table 103: Shanghai Henlius Biotech Inc. Financial Performance

Table 104: Global Claudin 18.2 Targeted Therapy Market, Competitive Benchmarking (In USD Billions)

Table 105: Global Claudin 18.2 Targeted Therapy Market, Competitive Dashboard

Table 106: Global Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 107: Global, Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), Segmentation By Therapy Type, 2025 – 2030

Table 108: Global, Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Table 109: Global, Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

List Of Figures

Figure 1: Global Claudin 18.2 Targeted Therapy Market, Overview Of Key Products - Product Examples

Figure 2: Global Claudin 18.2 Targeted Therapy Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Claudin 18.2 Targeted Therapy Market, Supply Chain Analysis

Figure 4: Global Claudin 18.2 Targeted Therapy Market, Major Raw Material Providers

Figure 5: Global Claudin 18.2 Targeted Therapy Market, Major Resource Providers

Figure 6: Global Claudin 18.2 Targeted Therapy Market, Major Manufacturers (Suppliers)

Figure 7: Global Claudin 18.2 Targeted Therapy Market, Major Distributors And Channel Partners

Figure 8: Global Claudin 18.2 Targeted Therapy Market, Key Technologies & Future Trends

Figure 9: Global Claudin 18.2 Targeted Therapy Market, Major Trends

Figure 10: Global Claudin 18.2 Targeted Therapy Market, Major End Users

Figure 11: Global Claudin 18.2 Targeted Therapy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Claudin 18.2 Targeted Therapy Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Claudin 18.2 Targeted Therapy Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Claudin 18.2 Targeted Therapy Market - TAM, US$ Billion, 2025

Figure 15: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Claudin 18.2 Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Claudin 18.2 Targeted Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Claudin 18.2 Targeted Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Claudin 18.2 Targeted Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Claudin 18.2 Targeted Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Global Claudin 18.2 Targeted Therapy Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 98: Global Claudin 18.2 Targeted Therapy Market - Company Scoring Matrix

Figure 99: Bristol Myers Squibb Company Financial Performance

Figure 100: Amgen Inc. Financial Performance

Figure 101: Astellas Pharma Inc. Financial Performance

Figure 102: Jiangsu Hengrui Medicine Co. Ltd. Financial Performance

Figure 103: Shanghai Henlius Biotech Inc. Financial Performance

Figure 104: Global Claudin 18.2 Targeted Therapy Market, Competitive Benchmarking (In USD Billions)

Figure 105: Global Claudin 18.2 Targeted Therapy Market, Competitive Dashboard

Figure 106: Global Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 107: Global, Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), Segmentation By Therapy Type, 2025 – 2030

Figure 108: Global, Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Figure 109: Global, Claudin 18.2 Targeted Therapy Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

COVID-19 Current Therapy Market Report 2026 - Global Outlook – By Drug Type (Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs...

Next-Generation Antibody Therapeutics Market Report 2026 - Global Outlook – By Types Of Antibodies (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types), By Therapeu...

Anti-Vascular Endothelial Growth Factor Therapeutics Market Report 2026 - Global Outlook – By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular...

Blood Cancer Drugs Market Report 2026 - Global Outlook – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), ...

Oligonucleotide Therapy Market Report 2026 - Global Outlook – By Type (Antisense Oligonucleotide, Aptamer, Other Types), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases...

Clopidogrel Market Report 2026 - Global Outlook – By Type (25 Milligram (Mg), 75 Milligram (Mg), 300 Milligram (Mg)), By Sales Channel (Direct Sale, Indirect Sale), By Application (Hospitals, Private Clinics, Retail Phar...

Neoantigen Targeted Therapies Market Report 2026 - Global Outlook – By Type (Monotherapy, Combination Therapy), By Immunotherapy Type (DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based...

Frequently Asked Questions

How big is the Claudin 18.2 Targeted Therapy Market?

The Claudin 18.2 Targeted Therapy market was valued at $1.6 billion in 2025, increased to $1.98 billion in 2026, and is projected to reach $4.61 billion by 2030.

What is the Claudin 18.2 Targeted Therapy market growth?

The global Claudin 18.2 Targeted Therapy market is expected to grow at a CAGR of 23.5% from 2026 to 2035 to reach $4.61 billion by 2035.

Who are the key players in Claudin 18.2 Targeted Therapy market?

Some Key Players in the Claudin 18.2 Targeted Therapy market Include, Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd. .

What is the anticipated growth trend for the Claudin 18.2 Targeted Therapy market?

Major trend in this market includes: Prominent Companies Pioneering Targeted Oncology Solutions. For further insights on this market. request a sample here

Which region has the most growth potential in the Claudin 18.2 Targeted Therapy market?

Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.